Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Deliver the broadest serotype coverage for babies1-3Prevenar 20™ helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1
Discover expanded serotype coverage
Loading Recommended by [Local body] for healthy babies, preterm infants, and children at increased risk for invasive pneumococcal disease1,6 Learn more Loading Demonstrated robust immune response against 20 serotypes after [__] doses with a safety profile comparable to Prevenar 13®1 Review trial results LoadingReferences:References:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Prevenar® (Pneumococcal 7-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2011.van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Local approval dates.
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​